Identification	O
of	O
Predictive	O
DNA	B:C0376452
Methylation	I:C0376452
Biomarkers	O
for	O
Chemotherapy	O
Response	O
in	O
Colorectal	O
Cancer	I:C1527249
.	O

Identification	O
of	O
Predictive	O
DNA	O
Methylation	I:C0376452
Biomarkers	B:C0041366
for	O
Chemotherapy	O
Response	O
in	O
Colorectal	O
Cancer	I:C1527249
.	O

Identification	O
of	O
Predictive	O
DNA	O
Methylation	I:C0376452
Biomarkers	O
for	O
Chemotherapy	B:C3665472
Response	O
in	O
Colorectal	O
Cancer	I:C1527249
.	O

Identification	O
of	O
Predictive	O
DNA	O
Methylation	I:C0376452
Biomarkers	O
for	O
Chemotherapy	O
Response	B:C0521982
in	O
Colorectal	O
Cancer	I:C1527249
.	O

Identification	O
of	O
Predictive	O
DNA	O
Methylation	I:C0376452
Biomarkers	O
for	O
Chemotherapy	O
Response	O
in	O
Colorectal	B:C1527249
Cancer	I:C1527249
.	O

Resistance	B:C0013203
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
(	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
)	O
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	O
of	O
colorectal	O
cancer	I:C1527249
(	O
colorectal	O
cancer	I:C1527249
)	O
and	O
posed	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

Resistance	O
to	O
5	B:C0016360
-	I:C0016360
Fluorouracil	I:C0016360
(	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
)	O
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	O
of	O
colorectal	O
cancer	I:C1527249
(	O
colorectal	O
cancer	I:C1527249
)	O
and	O
posed	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

Resistance	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
(	O
5	B:C0016360
-	I:C0016360
Fluorouracil	I:C0016360
)	O
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	O
of	O
colorectal	O
cancer	I:C1527249
(	O
colorectal	O
cancer	I:C1527249
)	O
and	O
posed	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

Resistance	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
(	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
)	O
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	O
of	O
colorectal	B:C1527249
cancer	I:C1527249
(	O
colorectal	O
cancer	I:C1527249
)	O
and	O
posed	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

Resistance	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
(	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
)	O
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	O
of	O
colorectal	O
cancer	I:C1527249
(	O
colorectal	B:C1527249
cancer	I:C1527249
)	O
and	O
posed	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

DNA	B:C0376452
methylation	I:C0376452
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
underlying	O
mechanisms	O
for	O
recurrent	O
disease	I:C0277556
and	O
its	O
contribution	O
to	O
the	O
development	O
of	O
drug	O
resistance	I:C0013203
remains	O
to	O
be	O
clarified	O
.	O

DNA	O
methylation	I:C0376452
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
underlying	O
mechanisms	O
for	O
recurrent	B:C0277556
disease	I:C0277556
and	O
its	O
contribution	O
to	O
the	O
development	O
of	O
drug	O
resistance	I:C0013203
remains	O
to	O
be	O
clarified	O
.	O

DNA	O
methylation	I:C0376452
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
underlying	O
mechanisms	O
for	O
recurrent	O
disease	I:C0277556
and	O
its	O
contribution	O
to	O
the	O
development	O
of	O
drug	B:C0013203
resistance	I:C0013203
remains	O
to	O
be	O
clarified	O
.	O

This	O
study	B:C0008972
aimed	O
to	O
determine	O
the	O
methylation	O
phenotype	O
in	O
colorectal	O
cancer	I:C1527249
for	O
identification	O
of	O
predictive	O
markers	O
for	O
chemotherapy	O
response	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
methylation	B:C0376452
phenotype	O
in	O
colorectal	O
cancer	I:C1527249
for	O
identification	O
of	O
predictive	O
markers	O
for	O
chemotherapy	O
response	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
methylation	O
phenotype	O
in	O
colorectal	B:C1527249
cancer	I:C1527249
for	O
identification	O
of	O
predictive	O
markers	O
for	O
chemotherapy	O
response	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
methylation	O
phenotype	O
in	O
colorectal	O
cancer	I:C1527249
for	O
identification	O
of	O
predictive	O
markers	B:C0041366
for	O
chemotherapy	O
response	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
methylation	O
phenotype	O
in	O
colorectal	O
cancer	I:C1527249
for	O
identification	O
of	O
predictive	O
markers	O
for	O
chemotherapy	B:C3665472
response	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
methylation	O
phenotype	O
in	O
colorectal	O
cancer	I:C1527249
for	O
identification	O
of	O
predictive	O
markers	O
for	O
chemotherapy	O
response	B:C0521982
.	O

We	O
performed	O
DNA	B:C0376452
methylation	I:C0376452
profiling	O
on	O
43	O
non-recurrent	O
and	O
five	O
recurrent	O
colorectal	O
cancer	I:C1527249
patients	O
using	O
the	O
Illumina	O
Infinium	I:C1880239
HumanMethylation450	I:C1880239
Beadchip	I:C1880239
assay	I:C1880239
.	O

We	O
performed	O
DNA	O
methylation	I:C0376452
profiling	O
on	O
43	O
non-recurrent	O
and	O
five	O
recurrent	O
colorectal	B:C1527249
cancer	I:C1527249
patients	O
using	O
the	O
Illumina	O
Infinium	I:C1880239
HumanMethylation450	I:C1880239
Beadchip	I:C1880239
assay	I:C1880239
.	O

We	O
performed	O
DNA	O
methylation	I:C0376452
profiling	O
on	O
43	O
non-recurrent	O
and	O
five	O
recurrent	O
colorectal	O
cancer	I:C1527249
patients	O
using	O
the	O
Illumina	B:C1880239
Infinium	I:C1880239
HumanMethylation450	I:C1880239
Beadchip	I:C1880239
assay	I:C1880239
.	O

In	O
addition	O
,	O
colorectal	B:C1527249
cancer	I:C1527249
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
global	O
methylation	I:C0376452
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
DNA	O
methylation	I:C0376452
inhibitor	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
(	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
)	O
.	O

In	O
addition	O
,	O
colorectal	O
cancer	I:C1527249
cells	B:C0334227
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
global	O
methylation	I:C0376452
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
DNA	O
methylation	I:C0376452
inhibitor	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
(	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
)	O
.	O

In	O
addition	O
,	O
colorectal	O
cancer	I:C1527249
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	B:C0521982
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
global	O
methylation	I:C0376452
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
DNA	O
methylation	I:C0376452
inhibitor	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
(	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
)	O
.	O

In	O
addition	O
,	O
colorectal	O
cancer	I:C1527249
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5	B:C0016360
-	I:C0016360
Fluorouracil	I:C0016360
and	O
global	O
methylation	I:C0376452
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
DNA	O
methylation	I:C0376452
inhibitor	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
(	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
)	O
.	O

In	O
addition	O
,	O
colorectal	O
cancer	I:C1527249
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
global	B:C0376452
methylation	I:C0376452
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
DNA	O
methylation	I:C0376452
inhibitor	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
(	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
)	O
.	O

In	O
addition	O
,	O
colorectal	O
cancer	I:C1527249
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
global	O
methylation	I:C0376452
levels	O
(	O
HT29	B:C0282639
and	O
SW48	O
)	O
were	O
treated	O
with	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
DNA	O
methylation	I:C0376452
inhibitor	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
(	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
)	O
.	O

In	O
addition	O
,	O
colorectal	O
cancer	I:C1527249
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
global	O
methylation	I:C0376452
levels	O
(	O
HT29	O
and	O
SW48	B:C0085983
)	O
were	O
treated	O
with	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
DNA	O
methylation	I:C0376452
inhibitor	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
(	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
)	O
.	O

In	O
addition	O
,	O
colorectal	O
cancer	I:C1527249
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
global	O
methylation	I:C0376452
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5	B:C0016360
-	I:C0016360
Fluorouracil	I:C0016360
and	O
DNA	O
methylation	I:C0376452
inhibitor	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
(	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
)	O
.	O

In	O
addition	O
,	O
colorectal	O
cancer	I:C1527249
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
global	O
methylation	I:C0376452
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
DNA	B:C0376452
methylation	I:C0376452
inhibitor	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
(	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
)	O
.	O

In	O
addition	O
,	O
colorectal	O
cancer	I:C1527249
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
global	O
methylation	I:C0376452
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
DNA	O
methylation	I:C0376452
inhibitor	O
5	B:C0049065
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
(	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
)	O
.	O

In	O
addition	O
,	O
colorectal	O
cancer	I:C1527249
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
global	O
methylation	I:C0376452
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
and	O
DNA	O
methylation	I:C0376452
inhibitor	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
(	O
5	B:C0049065
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
)	O
.	O

The	O
singular	O
and	O
combined	O
effects	O
of	O
these	O
two	O
drug	B:C1254351
classes	O
on	O
cell	O
viability	I:C0007620
and	O
global	O
methylation	I:C0376452
profiles	O
were	O
investigated	O
.	O

The	O
singular	O
and	O
combined	O
effects	O
of	O
these	O
two	O
drug	O
classes	B:C0456387
on	O
cell	O
viability	I:C0007620
and	O
global	O
methylation	I:C0376452
profiles	O
were	O
investigated	O
.	O

The	O
singular	O
and	O
combined	O
effects	O
of	O
these	O
two	O
drug	O
classes	O
on	O
cell	B:C0007620
viability	I:C0007620
and	O
global	O
methylation	I:C0376452
profiles	O
were	O
investigated	O
.	O

The	O
singular	O
and	O
combined	O
effects	O
of	O
these	O
two	O
drug	O
classes	O
on	O
cell	O
viability	I:C0007620
and	O
global	B:C0376452
methylation	I:C0376452
profiles	O
were	O
investigated	O
.	O

The	O
singular	O
and	O
combined	O
effects	O
of	O
these	O
two	O
drug	O
classes	O
on	O
cell	O
viability	I:C0007620
and	O
global	O
methylation	I:C0376452
profiles	B:C1979963
were	O
investigated	O
.	O

Our	O
genome	B:C2350277
-	I:C2350277
wide	I:C2350277
methylation	I:C2350277
study	I:C2350277
on	O
the	O
clinical	O
specimens	O
showed	O
that	O
recurrent	O
CRCs	O
exhibited	O
higher	O
methylation	O
levels	O
compared	O
to	O
non-recurrent	O
CRCs	O
.	O

Our	O
genome	O
-	I:C2350277
wide	I:C2350277
methylation	I:C2350277
study	I:C2350277
on	O
the	O
clinical	O
specimens	O
showed	O
that	O
recurrent	O
CRCs	B:C1527249
exhibited	O
higher	O
methylation	O
levels	O
compared	O
to	O
non-recurrent	O
CRCs	O
.	O

Our	O
genome	O
-	I:C2350277
wide	I:C2350277
methylation	I:C2350277
study	I:C2350277
on	O
the	O
clinical	O
specimens	O
showed	O
that	O
recurrent	O
CRCs	O
exhibited	O
higher	O
methylation	B:C0376452
levels	O
compared	O
to	O
non-recurrent	O
CRCs	O
.	O

Our	O
genome	O
-	I:C2350277
wide	I:C2350277
methylation	I:C2350277
study	I:C2350277
on	O
the	O
clinical	O
specimens	O
showed	O
that	O
recurrent	O
CRCs	O
exhibited	O
higher	O
methylation	O
levels	O
compared	O
to	O
non-recurrent	O
CRCs	B:C1527249
.	O

We	O
identified	O
4787	O
significantly	O
differentially	O
methylated	B:C0017337
genes	I:C0017337
(	O
P	O
<	O
0.05	O
)	O
;	O
3112	O
genes	O
were	O
hyper	O
-	O
while	O
1675	O
genes	O
were	O
hypomethylated	O
in	O
the	O
recurrent	O
group	O
compared	O
to	O
the	O
non-recurrent	O
.	O

We	O
identified	O
4787	O
significantly	O
differentially	O
methylated	O
genes	I:C0017337
(	O
P	O
<	O
0.05	O
)	O
;	O
3112	O
genes	B:C0017337
were	O
hyper	O
-	O
while	O
1675	O
genes	O
were	O
hypomethylated	O
in	O
the	O
recurrent	O
group	O
compared	O
to	O
the	O
non-recurrent	O
.	O

We	O
identified	O
4787	O
significantly	O
differentially	O
methylated	O
genes	I:C0017337
(	O
P	O
<	O
0.05	O
)	O
;	O
3112	O
genes	O
were	O
hyper	B:C0243095
-	O
while	O
1675	O
genes	O
were	O
hypomethylated	O
in	O
the	O
recurrent	O
group	O
compared	O
to	O
the	O
non-recurrent	O
.	O

We	O
identified	O
4787	O
significantly	O
differentially	O
methylated	O
genes	I:C0017337
(	O
P	O
<	O
0.05	O
)	O
;	O
3112	O
genes	O
were	O
hyper	O
-	O
while	O
1675	O
genes	B:C0017337
were	O
hypomethylated	O
in	O
the	O
recurrent	O
group	O
compared	O
to	O
the	O
non-recurrent	O
.	O

We	O
identified	O
4787	O
significantly	O
differentially	O
methylated	O
genes	I:C0017337
(	O
P	O
<	O
0.05	O
)	O
;	O
3112	O
genes	O
were	O
hyper	O
-	O
while	O
1675	O
genes	O
were	O
hypomethylated	B:C0243095
in	O
the	O
recurrent	O
group	O
compared	O
to	O
the	O
non-recurrent	O
.	O

Fifty	O
eight	O
and	O
47	O
of	O
the	O
significantly	O
hypermethylated	B:C0017337
and	I:C0017337
hypomethylated	I:C0017337
genes	I:C0017337
have	O
an	O
absolute	O
recurrent	O
/	O
non-recurrent	O
methylation	O
difference	O
of	O
≥	O
20	O
%	O
.	O

Fifty	O
eight	O
and	O
47	O
of	O
the	O
significantly	O
hypermethylated	O
and	I:C0017337
hypomethylated	I:C0017337
genes	I:C0017337
have	O
an	O
absolute	O
recurrent	O
/	O
non-recurrent	O
methylation	B:C0376452
difference	O
of	O
≥	O
20	O
%	O
.	O

Most	O
of	O
the	O
hypermethylated	B:C0017337
genes	I:C0017337
were	O
involved	O
in	O
the	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
which	O
is	O
a	O
key	O
regulator	O
for	O
apoptosis	O
while	O
the	O
hypomethylated	O
genes	I:C0017337
were	O
involved	O
in	O
the	O
PI3K	O
-	I:C0037080
AKT	I:C0037080
signaling	I:C0037080
pathway	I:C0037080
and	O
proliferation	O
process	O
.	O

Most	O
of	O
the	O
hypermethylated	O
genes	I:C0017337
were	O
involved	O
in	O
the	O
MAPK	B:C1518102
signaling	I:C1518102
pathway	I:C1518102
which	O
is	O
a	O
key	O
regulator	O
for	O
apoptosis	O
while	O
the	O
hypomethylated	O
genes	I:C0017337
were	O
involved	O
in	O
the	O
PI3K	O
-	I:C0037080
AKT	I:C0037080
signaling	I:C0037080
pathway	I:C0037080
and	O
proliferation	O
process	O
.	O

Most	O
of	O
the	O
hypermethylated	O
genes	I:C0017337
were	O
involved	O
in	O
the	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
which	O
is	O
a	O
key	O
regulator	O
for	O
apoptosis	B:C0162638
while	O
the	O
hypomethylated	O
genes	I:C0017337
were	O
involved	O
in	O
the	O
PI3K	O
-	I:C0037080
AKT	I:C0037080
signaling	I:C0037080
pathway	I:C0037080
and	O
proliferation	O
process	O
.	O

Most	O
of	O
the	O
hypermethylated	O
genes	I:C0017337
were	O
involved	O
in	O
the	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
which	O
is	O
a	O
key	O
regulator	O
for	O
apoptosis	O
while	O
the	O
hypomethylated	B:C0017337
genes	I:C0017337
were	O
involved	O
in	O
the	O
PI3K	O
-	I:C0037080
AKT	I:C0037080
signaling	I:C0037080
pathway	I:C0037080
and	O
proliferation	O
process	O
.	O

Most	O
of	O
the	O
hypermethylated	O
genes	I:C0017337
were	O
involved	O
in	O
the	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
which	O
is	O
a	O
key	O
regulator	O
for	O
apoptosis	O
while	O
the	O
hypomethylated	O
genes	I:C0017337
were	O
involved	O
in	O
the	O
PI3K	B:C0037080
-	I:C0037080
AKT	I:C0037080
signaling	I:C0037080
pathway	I:C0037080
and	O
proliferation	O
process	O
.	O

We	O
also	O
demonstrate	O
that	O
5	B:C0049065
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2	I:C0049065
'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
treatment	O
enhanced	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
which	O
resulted	O
in	O
significant	O
growth	O
inhibition	I:C1512773
compared	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
alone	O
in	O
hypermethylated	O
cell	I:C0085983
lines	I:C0085983
SW48	I:C0085983
.	O

We	O
also	O
demonstrate	O
that	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2	I:C0049065
'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
treatment	O
enhanced	O
response	B:C0521982
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
which	O
resulted	O
in	O
significant	O
growth	O
inhibition	I:C1512773
compared	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
alone	O
in	O
hypermethylated	O
cell	I:C0085983
lines	I:C0085983
SW48	I:C0085983
.	O

We	O
also	O
demonstrate	O
that	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2	I:C0049065
'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
treatment	O
enhanced	O
response	O
to	O
5	B:C0016360
-	I:C0016360
Fluorouracil	I:C0016360
which	O
resulted	O
in	O
significant	O
growth	O
inhibition	I:C1512773
compared	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
alone	O
in	O
hypermethylated	O
cell	I:C0085983
lines	I:C0085983
SW48	I:C0085983
.	O

We	O
also	O
demonstrate	O
that	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2	I:C0049065
'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
treatment	O
enhanced	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
which	O
resulted	O
in	O
significant	O
growth	B:C1512773
inhibition	I:C1512773
compared	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
alone	O
in	O
hypermethylated	O
cell	I:C0085983
lines	I:C0085983
SW48	I:C0085983
.	O

We	O
also	O
demonstrate	O
that	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2	I:C0049065
'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
treatment	O
enhanced	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
which	O
resulted	O
in	O
significant	O
growth	O
inhibition	I:C1512773
compared	O
to	O
5	B:C0016360
-	I:C0016360
Fluorouracil	I:C0016360
alone	O
in	O
hypermethylated	O
cell	I:C0085983
lines	I:C0085983
SW48	I:C0085983
.	O

We	O
also	O
demonstrate	O
that	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2	I:C0049065
'	I:C0049065
-	I:C0049065
deoxycytidine	I:C0049065
treatment	O
enhanced	O
response	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
which	O
resulted	O
in	O
significant	O
growth	O
inhibition	I:C1512773
compared	O
to	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
alone	O
in	O
hypermethylated	B:C0085983
cell	I:C0085983
lines	I:C0085983
SW48	I:C0085983
.	O

In	O
conclusion	O
,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	B:C0017337
in	O
recurrent	O
CRCs	O
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	O
targets	O
for	O
patients	O
with	O
chemoresistance	O
.	O

In	O
conclusion	O
,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	O
in	O
recurrent	O
CRCs	B:C1527249
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	O
targets	O
for	O
patients	O
with	O
chemoresistance	O
.	O

In	O
conclusion	O
,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	O
in	O
recurrent	O
CRCs	O
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	B:C0087111
targets	O
for	O
patients	O
with	O
chemoresistance	O
.	O

In	O
conclusion	O
,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	O
in	O
recurrent	O
CRCs	O
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	O
targets	O
for	O
patients	O
with	O
chemoresistance	B:C0013203
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	B:C0376452
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
colorectal	O
cancer	I:C1527249
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
colorectal	O
cancer	I:C1527249
and	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
-	O
mediated	O
restoration	O
of	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	B:C0017337
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
colorectal	O
cancer	I:C1527249
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
colorectal	O
cancer	I:C1527249
and	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
-	O
mediated	O
restoration	O
of	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	B:C1413177
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
colorectal	O
cancer	I:C1527249
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
colorectal	O
cancer	I:C1527249
and	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
-	O
mediated	O
restoration	O
of	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	B:C1418756
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
colorectal	O
cancer	I:C1527249
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
colorectal	O
cancer	I:C1527249
and	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
-	O
mediated	O
restoration	O
of	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	B:C1425700
,	O
and	O
CHL1	O
in	O
colorectal	O
cancer	I:C1527249
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
colorectal	O
cancer	I:C1527249
and	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
-	O
mediated	O
restoration	O
of	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	B:C1413393
in	O
colorectal	O
cancer	I:C1527249
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
colorectal	O
cancer	I:C1527249
and	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
-	O
mediated	O
restoration	O
of	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
colorectal	B:C1527249
cancer	I:C1527249
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
colorectal	O
cancer	I:C1527249
and	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
-	O
mediated	O
restoration	O
of	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
colorectal	O
cancer	I:C1527249
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
colorectal	B:C1527249
cancer	I:C1527249
and	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
-	O
mediated	O
restoration	O
of	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
colorectal	O
cancer	I:C1527249
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
colorectal	O
cancer	I:C1527249
and	O
5	B:C0049065
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
-	O
mediated	O
restoration	O
of	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
colorectal	O
cancer	I:C1527249
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
colorectal	O
cancer	I:C1527249
and	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
-	O
mediated	O
restoration	O
of	O
5	B:C0016360
-	I:C0016360
Fluorouracil	I:C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	I:C1518102
pathway	I:C1518102
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
colorectal	O
cancer	I:C1527249
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
colorectal	O
cancer	I:C1527249
and	O
5	O
-	I:C0049065
aza	I:C0049065
-	I:C0049065
2'-	I:C0049065
deoxycytidine	I:C0049065
-	O
mediated	O
restoration	O
of	O
5	O
-	I:C0016360
Fluorouracil	I:C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	B:C1518102
signaling	I:C1518102
pathway	I:C1518102
.	O

